Novel therapeutic approach against Epstein-Barr virus-associated tumors — ScienceDaily

0 Comments

A research team at LKS Faculty of Medicine, The University of Hong Kong (HKUMed) discovered that exosomes derived from V?2-T cells (Vδ2-T-Exos) can effectively control Epstein-Barr virus-associated tumours and induce T-cell anti-tumour immunity. The novel findings of Vδ2-T-Exos provide insights into new therapeutic approach for Epstein-Barr virus (EBV)-associated tumours. The ground-breaking findings have been published in the leading academic journal, Science Translational Medicine.

EBV infects about 95% of the human population and causes more than 200,000 cases of cancer each year and that around 2% of all cancer deaths are due to EBV-attributable malignancies. EBV-associated tumours include Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, gastric tumour and post-transplant lymphoproliferative disease, etc. Current treatment options for EBV-associated tumours are limited with considerably unwanted off-target toxicities and incomplete effectiveness for relapsed or refractory disease. V?2-T cells are innate-like T cells with anti-tumour potentials against EBV-associated tumours. Unfortunately, its clinical translation is limited because V?2-T cells from some cancer patients are difficult to be expanded. Exosomes are endosome-originated small extracellular vesicles that mediate intercellular communication. Compared with cell-based therapy, cell-free exosomes have advantages with higher safety, easier storage, and lower costs. However, the anti-tumour activity of exosomes derived from V?2-T cells (Vδ2-T-Exos) remains unknown.

Research findings

Herein, the team found that Vδ2-T-Exos contained death-inducing ligands (FasL and TRAIL) and immunostimulatory molecules (CD80, CD86, MHC class I and II). Vδ2-T-Exos targeted and efficiently killed EBV-associated tumour cells through FasL and TRAIL pathways and promoted EBV antigen-specific CD4 and CD8 T cell expansion. Administration of Vδ2-T-Exos effectively controlled EBV-associated tumours in immunodeficient and humanized mice. Because expanding V?2-T cells and preparing autologous Vδ2-T-Exos from cancer patients ex vivo in large scale is challenging, the team further explored the anti-tumour activity of allogeneic Vδ2-T-Exos in humanized mouse cancer models. Interestingly, the team found that allogeneic Vδ2-T-Exos

2020 Life Sciences Sector Report from CLSA Shows Strong Growth in Jobs, Investments and Therapeutic Pipeline in California

0 Comments

SAN FRANCISCO, SACRAMENTO, SAN DIEGO, Calif. & WASHINGTON–(BUSINESS WIRE)–Oct 7, 2020–

California Life Sciences Association (CLSA), the trade association representing California’s life sciences industry, today released the 2020 California Life Sciences Sector Report, which shows that California’s life sciences sector directly employed 323,723 people, generated $191.6 billion in revenue, is projected to attract $6.5 billion in venture capital (VC) and received $4.5 billion in funding from the NIH. Produced with PwC US, the 2020 snapshot highlights the strength of California’s biomedical sector – the largest cluster in the world – as evidenced by significant increases in employment, earnings, graduating science and engineering PhDs, VC investment, and potential new drugs and medical devices in the pipeline.

Key Highlights from 2020 California Life Sciences Sector Report

  • 4.0% increase in total life sciences jobs (up more than 12,000 from prior year), with companies directly employing 323,723 Californians – the most in the nation.
  • Total jobs created by the industry in California approaching 1 million, including approximately 621,000 indirect and induced employment.
  • There are 3,766 life sciences companies (up 348 from the prior year) in California, with 1,380 new therapies in the development pipeline, in addition to COVID-19 therapies and vaccines.
  • California biomedical companies attracted more than 11% of the state’s total VC investment.
  • The state’s universities graduated over 4,900 science and engineering PhDs, leading the nation by a wide margin. Universities and research institutes also brought in $4.49 billion in NIH grants, which also led the nation.

California Governor Gavin Newson commented: “For decades, California’s life sciences sector has had profound impacts on patients and their families in the Golden State and around the world. As we grapple with a global pandemic, the world increasingly looks to California for life-saving solutions. We are prouder than ever of this sector’s relentless pursuit

Novel Therapeutic Technology Developed and Manufactured by ADM Tronics for Origin, Inc., …

0 Comments

Northvale, NJ, Oct. 06, 2020 (GLOBE NEWSWIRE) — via NewMediaWire  — ADM Tronics Unlimited, Inc. (OTCQB: ADMT) has been advised that Origin, Inc. filed an Investigational Device Exemption (“IDE”) application with the FDA to conduct clinical studies to treat patients diagnosed with COVID-19 with its plasma-generated nitric oxide (“NO”) technology.  ADMT has been developing and has manufactured for Origin, Inc. the IonoJet™, which allows for targeted delivery of NO generated by a thermal plasma, produced from room air at the point of therapy.

Michael Preston, Chairman and President of Origin, Inc., stated, “Like other nitric oxide companies, we have recognized the potential ability of NO to stop the replication of corona viruses. We believe there may be limitations with other approaches, and we have worked to address these in a novel system that is designed to allow NO to be administered effectively. ADMT has been key to our development and will play an important part in our future.”

In an October 2, 2020 letter to Origin shareholders, Mr. Preston wrote, “We have today filed an Investigational Device Exemption (IDE) application with the U.S. Food and Drug Administration (FDA) under the Compassionate Use provisions of the Expanded Access pathway for the use of our plasma-generated nitric oxide (NO) in a physician-sponsored trial to treat patients diagnosed with COVID-19.”

“We are so pleased to see Origin’s progress,” stated Andre DiMino, President of ADMT. “And, we are doubly-pleased and excited to see that a technology we developed and manufactured at ADMT for Origin has the potential to help in the battle against this pandemic.”

Origin, Inc. is a Phase IIb clinical-stage biotechnology company that applies its proprietary technology to generate and deliver nitric oxide (NO) from a defined high-energy plasma stream.  Visit originww.com.

 About ADMT
 
ADMT is a diversified, technology-based developer and manufacturer